SX-682
Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 15 patients (estimated)
- Sponsors
- Roswell Park Cancer Institute
- Tags
- CXCR1 Inhibitor, CXCR2 Inhibitor, Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2014
- NCT Identifier
- NCT06622005
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.